These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 24136647

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F, Guzzardi G, Del Sette B, Sponghini AP, Matheoud R, Soligo E, Trisoglio A, Carriero A, Stecco A.
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [Abstract] [Full Text] [Related]

  • 3. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB.
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM.
    Neurosurgery; 2020 Oct 15; 87(5):931-938. PubMed ID: 32365185
    [Abstract] [Full Text] [Related]

  • 8. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.
    Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF.
    AJNR Am J Neuroradiol; 2011 May 15; 32(5):882-9. PubMed ID: 21330401
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.
    Kurokawa R, Baba A, Kurokawa M, Capizzano A, Hassan O, Johnson T, Ota Y, Kim J, Hagiwara A, Moritani T, Srinivasan A.
    AJNR Am J Neuroradiol; 2022 Feb 15; 43(2):202-206. PubMed ID: 35058300
    [Abstract] [Full Text] [Related]

  • 10. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
    Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP.
    Br J Radiol; 2012 Apr 15; 85(1012):382-9. PubMed ID: 21224297
    [Abstract] [Full Text] [Related]

  • 11. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N, Chiang G, Chakraborty S, Singh R, John Tsiouris A, Boockvar J, Kovanlikaya I.
    Neuroradiology; 2017 May 15; 59(5):499-505. PubMed ID: 28343250
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.
    Oncology; 2013 May 15; 85(3):191-5. PubMed ID: 24008924
    [Abstract] [Full Text] [Related]

  • 18. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo KM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ.
    Neuro Oncol; 2016 May 15; 18(5):735-43. PubMed ID: 26538618
    [Abstract] [Full Text] [Related]

  • 19. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF.
    Radiology; 2014 Apr 15; 271(1):200-10. PubMed ID: 24475840
    [Abstract] [Full Text] [Related]

  • 20. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.
    Cancer; 2013 Oct 01; 119(19):3479-88. PubMed ID: 23821555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.